Akorn Inc. (NasdaqGM:AKRX) a niche generic pharmaceutical company, reported financial results for the third quarter ended September 30, 2010. Consolidated revenue for the third quarter of 2010 was $21.7 million, compared to $19.4 million in the third quarter of 2009, representing an increase of 12%. Third quarter revenue for the core business, which consists of ophthalmic, hospital drugs & injectables and contract services, totaled $21.7 million in 2010 compared to $10.0 million for the same quarter in 2009, an increase of 118%. Sequential quarter core revenue grew 7%, from $20.2 million to $21.7 million.
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States.
Boston Private Financial Holdings Inc. (NasdaqGS:BPFH) announced on November 2, 2010 that members of its executive management team will host an investor event on Wednesday, Nov. 3 at 4 p.m. at The Langham Hotel in Boston, MA. Clayton Deutsch, President and Chief Executive Officer, and David Kaye, Chief Financial Officer, will make a presentation and take questions from the audience. The event will webcast and can be accessed on the Investor Relations page of the Company’s website http://ir.bostonprivate.com/.
Boston Private Financial Holdings, Inc. operates as the multi-bank holding company in the United States. The company provides private banking, investment management, and wealth advisory services to high net worth individuals, families, small and medium-sized businesses, and institutions. It offers various deposit products, including checking accounts, demand deposits, NOW accounts, savings accounts, money market accounts, and certificates of deposit.
PDL BioPharma, Inc. (NasdaqGS:PDLI) announced on November 2, 2010 that the Company will release its third quarter financial results on Wednesday, November 10, 2010 after the markets close. PDL’s management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results. To access the live conference call via phone, please dial (866) 271-5140 from the United States and Canada or (617) 213-8893 internationally. The conference ID is 98631412. To access the live and subsequently archived webcast of the conference call, go to the Company’s website at http://www.pdl.com and go to “Company Presentations & Events.
PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents primarily cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies.
NetSol Technologies, Inc. ("NetSol" or the "Company") (Nasdaq:NTWK) (Nasdaq Dubai:NTWK), a U.S. corporation providing global business services and enterprise application solutions to private and public sector organizations worldwide, today announced that management will hold a conference call on Wednesday, November 10, 2010 at 11:00 a.m. EST (8:00 a.m. Pacific) to discuss its financial results for the first quarter of fiscal year 2011.
NetSol Technologies, Inc. (Nasdaq:NTWK) (Nasdaq Dubai:NTWK) is a worldwide provider of global IT and enterprise application solutions. Since its inception in 1995, NetSol has used its BestShoring™ practices and highly experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions. Specialized by industry, these product and services offerings include credit and finance portfolio management systems, SAP consulting and services, custom development, systems integration, and technical services for the global Financial, Leasing, Insurance, Energy, and Technology markets.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations.